Group purchasing organizations and purchasing groups, affiliations, and coalitions
We realize that in healthcare, you can’t go it alone. It takes partners and associates coming together in collaboration to achieve efficient, cost-effective care for patients. We also understand the financial and operational pressures faced by today’s hospitals and healthcare systems, because we are a hospital too. Group purchasing organizations (GPOs) and purchasing groups (PGs) help hospitals by shouldering the burden of negotiating the best member pricing and benefits with quality suppliers. At Mayo Clinic Laboratories, we welcome the opportunity to serve members by establishing relationships with their GPOs and PGs to provide member access to our broad esoteric testing menu and services.
Building laboratory value
The financial pressure on hospitals continues. To help, we can support hospital laboratories by evaluating current utilization, capacity, and processes to help reduce waste, find efficiencies, and maximize capabilities for optimal financial performance.
We also offer support in building and expanding laboratory outreach programs. Our experienced, industry-leading outreach consultants offer unparalleled insights and experience to help hospital-based laboratories evolve from cost-centers to revenue generators. Learn more about how we can support laboratories’ optimization and revenue-generation goals.
Driving efficiency through consolidation
Most hospital laboratories find themselves sending tests to an increasing number of commercial and specialty reference laboratories. Managing the complexities of these various relationships increases operational burden, staff workload, and inconsistencies in testing methods and interpretation of results.
Hospitals and health systems can optimize their laboratory testing referrals by leveraging our extensive test menu, which includes advanced diagnostics, cutting-edge technology, and clinically relevant new tests across our full spectrum of medical subspecialties.
“The type of service we provide is really tailored to the needs of the hospital or to the healthcare system. And their patients are no different than the patients that walk through our doors.”
William Morice, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories
Sharing knowledge and empowering staff
We support care teams by providing insights and education as they strive to solve the most complex medical challenges. Our education offerings range from conferences to on-demand programs to webinars — many of which offer CME credit. View our extensive educational offerings.
In addition, hospital and laboratory staff have direct access to Mayo Clinic physicians and scientists, who can help with optimizing test orders and interpreting results. Mayo Clinic Laboratories provides each client with a dedicated team of account, clinical, and laboratory technical professionals.
Prioritizing patient care
With guidance from our practicing physicians, we continuously develop testing algorithms, invest in research, and develop new tests so that patients have access to the best testing available. As a hospital-based reference laboratory, our focus is helping clients prevent overutilization of laboratory testing, drive efficiency through consolidation of send-out testing, and generate hospital revenue by establishing and growing lab outreach programs. And, we provide benefits only available through a connection with a world-class medical institution: access to our Mayo Clinic physicians and consultants, educational offerings, and the most cutting-edge, clinically-based testing available in the market.
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent industry news and how clinical diagnostics are powering more personalized care.
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
This week's research roundup feature: Only 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response. We developed an "immunotumoroid" cell model system that recapitulates the tumor, its microenvironment, and necessary immune system components in patient-derived spheroids to enable ex vivo assessment of tumor response to ICI therapy.
The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and excellent service. When aligning testing with community awareness and patient needs, the laboratory outreach program can strategically plan for future success.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he discusses sustainability in laboratories and the interconnectivity of environmental health and public health.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Chancey Christenson, M.D., about the lab's important role in healthcare.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including Medical Laboratory Professionals Week, recent healthcare conferences, advocacy efforts, measles, and bird flu.
With nearly 30 years at Mayo Clinic, Sherri Hawkins has served in a wide range of laboratory-related roles. Beginning as a laboratorian on the bench and now serving as Group Purchasing Organization (GPO) manager, Sherri has been able to unite her two career passions — laboratory testing and business.
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
This week's research roundup feature: R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.
As we prepare to celebrate this year's Lab Week, the Mayo Collaborative Services Education team not only wants to highlight your important work as medical laboratory professionals and pathologists, but also help you feel more confident in your role by sharing the following educational resources that may give you additional knowledge and opportunities to advance in your career.